Home Cytokines and Immune Cell Markers Interferon-Gamma Test: Immune Activation, Infection Response, and T-Cell Activity

Interferon-Gamma Test: Immune Activation, Infection Response, and T-Cell Activity

By
Vita Library
-
23
Learn how serum interferon-gamma tests, IFN-γ release assays, and anti-IFN-γ antibody tests differ, and what high, low, positive, or indeterminate results may mean.

An interferon-gamma test can mean several different laboratory procedures, and the distinction changes the interpretation. Interferon-gamma, or IFN-γ, is a cytokine made mainly by activated T cells and natural killer cells. It helps macrophages kill organisms that survive inside cells, strengthens antigen presentation, and supports a type 1 immune response. A laboratory may measure IFN-γ already circulating in serum, measure how much a person’s blood cells release after stimulation, or test for antibodies that block IFN-γ. The best-known interferon-gamma release assay exposes blood to tuberculosis proteins and asks whether sensitized T cells respond; it is not a general IFN-γ level. Other stimulated assays assess pathogen-specific T-cell memory or broader immune function. Because IFN-γ changes rapidly, acts mainly within tissues, and can be affected by medications and sample handling, no single result gives a complete picture of infection, inflammation, or T-cell health. The exact test name, controls, units, and reason for ordering must be reviewed first.

  • Serum IFN-γ, an antigen-specific release assay, and an anti-IFN-γ autoantibody test answer different questions.
  • A positive tuberculosis IGRA indicates immune sensitization to tuberculosis antigens; it does not distinguish latent infection from active disease.
  • High circulating IFN-γ can accompany immune activation but is not specific to one infection or inflammatory disorder.
  • A weak stimulated response may reflect immunosuppression, too few responsive cells, poor specimen handling, or a technical control failure.
  • Neutralizing anti-IFN-γ autoantibodies can cause an acquired immune deficiency with unusual intracellular infections.

Table of Contents

How Interferon-Gamma Coordinates Cellular Immunity

IFN-γ is the only type II interferon. It differs from type I interferons such as interferon-alpha and interferon-beta in its source, receptor, and dominant biological roles. Natural killer cells can release IFN-γ early during infection. Later, antigen-specific CD4 T helper 1 cells and CD8 cytotoxic T cells become major producers. Other lymphocyte populations can contribute in selected settings.

The cytokine’s central job is to make cellular immunity more effective. When IFN-γ binds its receptor, cells activate the JAK-STAT signaling pathway and change expression of many genes. Macrophages become better able to contain and kill organisms that live within phagocytic compartments or otherwise evade extracellular defenses. Cells increase major histocompatibility complex expression, improving the display of antigens to T cells. IFN-γ also helps direct immune responses toward a type 1 pattern and can restrain alternative immune programs.

This biology is particularly important in defense against mycobacteria, Salmonella, certain fungi, and other intracellular pathogens. Inherited defects affecting IFN-γ production, its receptor, or the interleukin-12–IFN-γ circuit can cause severe or disseminated infections. Acquired antibodies that neutralize IFN-γ can create a similar functional problem later in life.

IFN-γ is protective, but sustained or excessive activity can also promote inflammation and tissue damage. It participates in some autoimmune diseases, inflammatory syndromes, transplant responses, and severe infections. Its effect depends on timing and location. A strong local response at an infected site may be useful even when the blood concentration is low. A high serum level may represent spillover from widespread activation rather than an exact measure of how effectively cells are controlling a pathogen.

Interferon-gamma should not be confused with interferon-alpha testing. IFN-α is a type I interferon involved prominently in early antiviral signaling. An assay for one does not substitute for an assay of the other.

Three Very Different Tests Called Interferon-Gamma Testing

A report that contains the words “interferon gamma” may represent one of three broad categories.

A direct IFN-γ concentration measures cytokine already present in serum, plasma, cerebrospinal fluid, or another body fluid. Results are commonly reported in picograms per milliliter, although units and detection limits vary. Direct measurement can be part of a specialist cytokine panel, research protocol, or evaluation of a specific inflammatory condition. It is rarely diagnostic by itself because many disorders can raise IFN-γ and because blood levels may not reflect tissue activity.

A stimulated IFN-γ release assay measures what immune cells produce after laboratory stimulation. Blood is divided among tubes or wells containing an antigen, a negative control, and a positive control. The laboratory then measures released IFN-γ or counts IFN-γ–producing cells. Tuberculosis IGRAs use antigens selected from Mycobacterium tuberculosis. Other assays may use viral, fungal, vaccine, donor, or nonspecific stimulants. The result describes a response to that particular stimulus under the test conditions, not the person’s resting serum IFN-γ level.

An anti-IFN-γ autoantibody assay looks for antibodies directed against the cytokine. Some methods show binding only. Functional assays determine whether the antibodies actually block IFN-γ signaling, often by assessing downstream STAT1 phosphorylation or response-gene activation. A high binding titer does not always equal clinically important neutralization, so the functional result matters.

A fourth related category includes research tests of IFN-γ messenger RNA, intracellular cytokine staining, ELISpot, and multiparameter flow cytometry. These methods can identify which cells produce IFN-γ and whether they make other cytokines at the same time. They are useful for detailed immune profiling but are not interchangeable with a routine serum assay or a commercial tuberculosis IGRA.

The words “positive,” “high,” “low,” and “indeterminate” therefore have test-specific meanings. A positive antigen-release assay means stimulated cells responded above a defined threshold. A high serum value means the resting specimen contained more cytokine than the laboratory’s comparator. An indeterminate IGRA usually means the controls did not support a valid positive-or-negative interpretation. Reading the result without the method can lead to exactly the wrong conclusion.

How Interferon-Gamma Release Assays Work

The tuberculosis IGRA is the most common reason people encounter IFN-γ testing. It measures cell-mediated immune recognition of selected tuberculosis antigens. Blood is incubated with antigen-containing material, and IFN-γ released by sensitized T cells is compared with controls. Commercial formats either quantify cytokine in the fluid above the cells or count individual cells that produce it.

The negative control, often called the nil control, estimates baseline IFN-γ and nonspecific signal. The positive control stimulates cells without relying on tuberculosis recognition. It shows whether lymphocytes can respond and whether the specimen was viable and processed adequately. The antigen result is adjusted for background. A valid positive result requires sufficient antigen response, while a valid negative result requires an acceptable positive-control response and manageable background.

A positive tuberculosis IGRA supports infection with M. tuberculosis but does not reveal when infection occurred. It cannot by itself distinguish latent tuberculosis infection from active tuberculosis disease. A person with symptoms, an abnormal chest image, or epidemiologic risk needs further assessment such as imaging and microbiologic testing. A negative result reduces the likelihood of infection but does not rule it out in a person with severe immunosuppression, very recent exposure, active severe illness, or a high pretest probability.

Unlike the tuberculin skin test, an IGRA is not expected to become positive solely because of bacille Calmette-Guérin vaccination. That makes it useful in BCG-vaccinated people. However, immune responses to a small number of related nontuberculous mycobacteria may affect specificity, and laboratory handling remains important.

Other pathogen-specific IFN-γ release assays follow a similar principle but have different validation. Some assess cytomegalovirus-specific T-cell immunity in transplant recipients; others have been studied for SARS-CoV-2, fungal infection, or vaccine responses. A result validated for one antigen and clinical purpose should not be generalized to another. The size of an antigen-specific IFN-γ response is not a universal measure of protection.

Global immune-function assays use nonspecific stimulants to trigger both innate and adaptive cells. A low release can correlate with infection risk in certain transplant or critical-care populations, but performance varies and thresholds are not universal. These tests complement, rather than replace, clinical assessment, drug levels, white-cell counts, and pathogen surveillance.

What High Interferon-Gamma May Mean

A high serum or plasma IFN-γ result shows that the cytokine was detectable above the laboratory’s reference value at the time of collection. It does not identify the source cell or the cause.

Infection-related activation is one possibility. Intracellular bacterial, mycobacterial, viral, fungal, and parasitic infections can stimulate natural killer cells and T cells. The circulating concentration may vary with infection stage, pathogen burden, tissue involvement, and treatment. A pathogen-specific test is needed to diagnose the infection; IFN-γ cannot replace culture, nucleic-acid testing, antigen detection, serology, imaging, or tissue analysis.

Autoimmune and inflammatory activity can also increase IFN-γ. Type 1 T-cell responses may contribute to inflammatory bowel disease, autoimmune thyroid disease, inflammatory arthritis, skin disease, and other immune-mediated conditions. The association is not specific enough for a serum IFN-γ result to establish any one diagnosis. A broad cytokine panel may show a pattern of immune activation, but even a pattern must be interpreted in the context of symptoms and standard disease markers.

Hyperinflammatory syndromes may involve substantial IFN-γ activity. Macrophage activation syndrome and hemophagocytic lymphohistiocytosis can feature intense T-cell and macrophage signaling. The diagnosis depends on the clinical syndrome and findings such as persistent fever, cytopenias, organ enlargement, liver abnormalities, coagulation changes, ferritin elevation, triglycerides, fibrinogen, soluble IL-2 receptor, and evidence of organ dysfunction. A high IFN-γ value alone is insufficient.

Cell therapy and immune-modulating treatment can alter IFN-γ. T-cell–engaging therapies, checkpoint inhibitors, vaccines, cytokine therapies, and reduction of immunosuppression may increase cellular activation. Conversely, glucocorticoids, calcineurin inhibitors, antimetabolites, JAK inhibitors, and lymphocyte-depleting therapies can suppress production or response. The medication list and timing in relation to dosing are essential.

Laboratory and specimen factors can create an unexpected high value. Delayed separation of serum or plasma may allow cells to continue releasing cytokine. Hemolysis, heterophile antibodies, rheumatoid factor, or platform-specific interference can affect some immunoassays. A result that is biologically implausible should be confirmed using appropriate laboratory troubleshooting rather than accepted automatically.

A high result is not necessarily evidence of strong immune protection. IFN-γ may be elevated because immune cells are struggling against a large pathogen burden or because inflammation is poorly regulated. Protective effectiveness is judged by clinical outcome and pathogen control, not by cytokine concentration alone.

What Low IFN-γ or a Weak Release Response May Mean

Low or undetectable IFN-γ in an unstimulated serum sample is often expected. Cytokines act at low concentrations, may be produced mainly in tissues, and can be cleared rapidly. An undetectable direct level does not prove T-cell failure.

A low stimulated response is more specific to the assay context. In an antigen-specific test, it may mean that the person has not developed memory T cells recognizing that antigen. It can also occur soon after exposure, after immune responses have waned, or when immunosuppression prevents a measurable response. A negative tuberculosis IGRA must therefore be weighed against exposure risk, symptoms, and immune status.

An indeterminate or invalid result is different from a negative result. High background in the nil control can make the antigen response uninterpretable. A poor positive-control response can result from lymphopenia, advanced immunosuppression, severe acute illness, young age, technical error, delayed incubation, incorrect tube filling, inadequate mixing, or unsuitable transport temperature. Repeating the test with proper handling or using an alternative method may be appropriate.

T-cell quantity matters. A low CD4 count, low CD8 count, or broad lymphopenia can reduce the number of cells available to release IFN-γ. Yet normal counts do not guarantee normal function. Lymphocyte proliferation assays, intracellular signaling studies, and pathogen-specific functional tests may be needed when a qualitative defect is suspected.

Defects in the interleukin-12–IFN-γ pathway can impair production or response. Some inherited conditions present in childhood with disseminated or recurrent mycobacterial and Salmonella infections. The affected step matters: a person may produce little IFN-γ, may fail to respond to it, or may have a defect elsewhere in macrophage activation. Specialist functional testing and genetic analysis are used to distinguish these possibilities.

Medications can lower stimulated release. Glucocorticoids and several transplant, cancer, and autoimmune therapies suppress T-cell activation or cytokine production. The result should not be interpreted without dose, duration, and timing. Recovery after treatment may lag behind changes in the blood count.

Finally, a weak IFN-γ result is not synonymous with “weak immunity” overall. Antibodies, complement, neutrophils, type I interferons, tissue barriers, and other cytokines may function normally. It describes one measured response under one set of laboratory conditions.

Anti-Interferon-Gamma Autoantibodies and Acquired Immune Deficiency

Neutralizing anti-IFN-γ autoantibodies are an important but uncommon cause of adult-onset immune deficiency. The antibodies bind IFN-γ and prevent it from activating its receptor effectively. As a result, macrophage responses to intracellular organisms can be impaired even though routine immunoglobulin levels and lymphocyte counts may be relatively preserved.

The syndrome is reported most often in adults from parts of Southeast and East Asia, although it can occur elsewhere. Clinical clues include disseminated nontuberculous mycobacterial infection, recurrent lymph-node infection, osteomyelitis, skin lesions, or infections involving multiple organs. Salmonella, Talaromyces, Cryptococcus, varicella-zoster virus, and other opportunistic pathogens may occur. The pattern—not a single organism—raises suspicion.

Testing usually begins with an assay that detects anti-IFN-γ antibodies. Because some binding antibodies may not meaningfully block function, confirmation with a neutralization assay is valuable. Functional methods may assess whether patient plasma prevents IFN-γ–induced STAT1 phosphorylation, gene expression, or another cellular response. Titer and neutralizing capacity can be followed, but their relationship with infection activity is not perfectly linear.

This condition differs from antibodies against type I interferons. Anti-IFN-α or anti-IFN-ω antibodies are associated especially with susceptibility to severe viral disease. Anti-IFN-γ antibodies impair macrophage-centered defense against intracellular pathogens. A laboratory report should specify the cytokine target.

Treatment focuses first on identifying and controlling infection, often with prolonged multidrug antimicrobial therapy. In difficult or relapsing cases, specialists may consider treatments intended to reduce autoantibody production or activity. Management is individualized because evidence is limited and immune suppression can worsen active infection. Monitoring includes microbiology, imaging, organ function, inflammatory markers, clinical response, and sometimes antibody or functional assays.

A positive antibody result in someone without the characteristic infection pattern should be interpreted cautiously. The clinical significance depends on neutralizing function, concentration, persistence, and the person’s history. Conversely, a strong clinical pattern may justify repeat or more specialized testing after an initially negative binding assay.

Specimen Handling, Controls, and Result Limitations

Interferon-gamma testing is highly sensitive to the preanalytic process. Direct cytokine measurement usually requires serum or plasma to be separated promptly and stored under validated conditions. Repeated freezing and thawing may affect recovery. The laboratory’s specimen instructions take priority because serum, EDTA plasma, heparin plasma, and cell-culture supernatants are not automatically equivalent.

Stimulated release assays have additional requirements because living cells must remain functional. Blood volume in each tube affects the ratio of cells to antigen. Tubes must be mixed enough to coat the inner surface without damaging cells. Incubation generally must begin within a defined period and at a controlled temperature. Delays can reduce response or increase variability.

Controls are part of the result, not optional technical details. The nil value shows background. The mitogen or positive control tests general responsiveness. Some assays include multiple antigen tubes designed to recruit different T-cell populations. Clinicians should review the individual values when the final category does not fit the clinical picture.

Cutoffs are assay-specific. A numerical result close to a threshold may change category on repeat testing because of ordinary biological and analytical variation. Serial testing in low-risk people can produce conversions and reversions near the cutoff. Decisions should consider pretest probability and the consequences of treatment rather than treating a borderline number as absolute.

For direct serum assays, “normal ranges” may come from small groups of healthy adults and may not be diagnostic thresholds. Values from two manufacturers can differ because antibodies recognize different epitopes, calibrators differ, and one platform may be more sensitive. Trend testing is most interpretable on the same method.

Other limitations include cytokine-binding proteins, therapeutic antibodies, endogenous autoantibodies, heterophile interference, and altered cell composition. A person with many activated lymphocytes may generate more total IFN-γ than someone with fewer cells even if each cell has similar function. Reporting the response per volume of blood does not fully separate cell number from cell quality.

Clinical Follow-Up and Related Immune Tests

The follow-up depends on the test type and the reason it was ordered. For a positive tuberculosis IGRA, clinicians assess symptoms, exposure history, chest imaging, and the likelihood of active disease. Sputum or other specimens may be tested when disease is possible. Treatment decisions account for age, medical conditions, medication interactions, and risk of progression.

For a high direct IFN-γ level, the next step is usually not to repeat a large cytokine panel automatically. The clinician looks for a focused explanation: infection, autoimmune inflammation, hyperinflammation, treatment effect, or an organ-specific process. A complete blood count, liver and kidney tests, cultures or molecular pathogen testing, imaging, and standard inflammatory markers often provide more actionable information.

When cellular immune function is the concern, a lymphocyte subset panel shows how many T, B, and natural killer cells are present. A lymphocyte proliferation test evaluates cell division after mitogen or antigen stimulation. Flow cytometry can identify activation and memory populations, while targeted assays can examine receptor signaling, degranulation, cytotoxicity, or cytokine production.

For recurrent disseminated intracellular infections, evaluation may include anti-IFN-γ antibodies, functional neutralization, HIV testing, immunoglobulins, genetic studies, and pathogen-specific workup. Testing should be coordinated by specialists because sample requirements and result interpretation are complex.

Urgent care is needed for severe breathing difficulty, confusion, low blood pressure, new neurologic symptoms, rapidly spreading skin lesions, persistent fever with deterioration, or signs of sepsis. A pending IFN-γ result should never delay treatment of a suspected serious infection.

A useful interpretation discussion answers five questions: What exactly was stimulated or measured? Were the controls valid? Does the result fit the exposure and symptom timeline? Could medications or cell counts explain it? What clinical decision changes because of it? Those questions prevent a specialized immune signal from being mistaken for a stand-alone diagnosis.

References

Disclaimer

This article is for general education and is not a diagnosis or treatment plan. Interferon-gamma results depend on the exact assay, controls, specimen handling, infection risk, medications, and immune status, so they should be reviewed by a qualified clinician. Seek urgent medical care for severe infection symptoms, breathing difficulty, confusion, shock, or rapidly worsening illness.

RELATED ARTICLESMORE FROM AUTHOR